00_transportation_isolation_system_1

Results released from first clinical trial using Danoprevir to treat COVID-19

pharmafile | March 25, 2020 | News story | Research and Development COVID, COVID-19, Wuhan, china coronavirus, coronavirus 

The first clinical trial using danoprevir (Ganovo) in treating COVID-19 has released its results, showing that it is safe and well tolerated in patients.

The data was published in medRxiv, and the trial saw 19 patients in a 4 to 12-day treatment of danoprevir combined with ritonavir.  After this initial treatment, the first negative test occurred at a median of 2 days and ranged from 1 to 8 days. CT scans revealed that the obvious absorption rate occurred at a median of 3 days ranging from 2 to 4 days.

Eleven patients were discharged from the hospital after they met all four of these conditions: normal body temperature for 3 days, improved respiratory symptoms, lung imaging showing absorption and recovery of acute exudative lesion and two consecutive RT-PCR negative tests of SARS-CoV-2 nucleotide acid.

Dr. Jinzi  Wu, Chairman and CEO of Ascletis, commented on the results: “We are pleased that the first clinical study using Ganovo®(danoprevir) to treat COVID-19 patients was published in medRxiv. Ascletis is proud of repurposing our HCV drug, danoprevir, as a potential therapeutic option for COVID-19.”

Conor Kavanagh

Related Content

Gilead’s Veklury recommended by NICE for COVID-19 treatment

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …

diana-polekhina-zbsthwt9vlc-unsplash_2

Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine

Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational …

Latest content